Cianna Medical has secured an additional FDA 510(k) clearance for the SAVI SCOUT radar localisation system, enabling the reflector to be placed at the lumpectomy site up to 30 days before surgical removal.

SCOUT a medical device uses radar in human tissue for localising and directing the removal of non-palpable breast lesions.

Cianna Medical president and CEO Jill Anderson said: “Extending the timeframe between tumor localisation and surgical intervention has the potential to improve scheduling flexibility for patients, physicians and health systems, further supporting the use of radar as a desirable platform technology for tumour localisation.

"In cases where localisation was performed, targeted lesions and reflectors were removed with success and without any observed reflector migration."

“SCOUT is a novel technology, requiring no radiation or invasive wires, that has demonstrated the potential to drive value by reducing costs and improving patient outcomes.”

Data that was peer-reviewed and recently published in the July issue of Annals of Surgical Oncology indicated 100% surgical success, with significantly lower repeat surgery rates than those using wire localisation.

In cases where localisation was performed, targeted lesions and reflectors were removed with success and without any observed reflector migration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In an another key study finding, researchers found that the SCOUT reflector could detect up to 5cm from the handpiece.

The FDA-cleared SCOUT system comes with a reflector that is placed at the tumour site up to 30 days before a lumpectomy or surgical biopsy.

During this procedure, surgeons can scan the breast using the SCOUT handpiece, which in turn emits infrared light and a micro-impulse radar signal that helps with detection of the location of the reflector.

Surgeons can exactly locate the reflector, along with the target tissue.

Due to this higher level of localisation precision, better surgical planning is possible to improve cosmetic results.